Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 44, Issue 4, Pages 1032-1040Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2014.2259
Keywords
interleukin-6; Janus kinase; signal transducer and activator of transcription 3; therapies; colorectal cancer
Categories
Ask authors/readers for more resources
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer hallmarks' through downstream activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway. Additionally, dysregulation of the interleukin (IL)-6-mediated JAK/STAT3 signaling pathway is closely related to the development of diverse human solid tumors including colorectal cancer (CRC). On this basis, modulation of the IL-6/JAK/STAT3 signaling pathway is currently being widely explored to develop novel therapies for CRC. The present review details the mechanisms and roles of the IL-6/JAK/STAT3 pathway in CRC, describes current therapeutic strategies, and the search for potential therapeutic approaches to treat CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available